Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tscan Therapeutics Inc (TCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TCRX (1-star) is a SELL. SELL since 2 days. Profits (-22.22%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $9
1 Year Target Price $9
| 4 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.89% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.23M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 8 | Beta 0.97 | 52 Weeks Range 1.02 - 7.89 | Updated Date 06/30/2025 |
52 Weeks Range 1.02 - 7.89 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1669.74% |
Management Effectiveness
Return on Assets (TTM) -30.45% | Return on Equity (TTM) -78.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -75425123 | Price to Sales(TTM) 17.92 |
Enterprise Value -75425123 | Price to Sales(TTM) 17.92 | ||
Enterprise Value to Revenue 7.64 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 52314000 | Shares Floating 40710731 |
Shares Outstanding 52314000 | Shares Floating 40710731 | ||
Percent Insiders 0.24 | Percent Institutions 87.81 |
Analyst Ratings
Rating 3 | Target Price 9 | Buy 4 | Strong Buy 4 |
Buy 4 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tscan Therapeutics Inc
Company Overview
History and Background
TScan Therapeutics, Inc. is a biopharmaceutical company focused on developing T-cell receptor (TCR)-engineered T cell therapies for the treatment of cancer. Founded in 2018, it leverages its TargetScan and T-Scan platforms to identify and develop novel immunotherapies. The company went public in 2020.
Core Business Areas
- Oncology Immunotherapy: Development of TCR-engineered T cell therapies for hematologic malignancies and solid tumors. Focus on identifying relevant tumor targets and engineering T cells to specifically target and kill cancer cells.
Leadership and Structure
The company's leadership team includes key executives in R&D, clinical development, and operations. The organizational structure is typical of a biotechnology company, with departments dedicated to research, development, clinical trials, manufacturing, and business operations.
Top Products and Market Share
Key Offerings
- TSC-100: TCR-T cell therapy targeting minor histocompatibility antigens (miHAs) for hematologic malignancies post-transplant. Currently in clinical trials. No market share data available as the product is in clinical development. Competitors developing similar allogeneic cell therapies include Atara Biotherapeutics (ATRA) and Gamida Cell (GMDA).
- TSC-101: TCR-T cell therapy targeting a novel tumor antigen for solid tumors. Currently in clinical trials. No market share data available as the product is in clinical development. Competitors in the broader solid tumor cell therapy space include Iovance Biotherapeutics (IOVA) and Adaptimmune Therapeutics (ADAP).
Market Dynamics
Industry Overview
The oncology immunotherapy market is rapidly growing, driven by the success of checkpoint inhibitors and CAR-T cell therapies. The market is characterized by intense competition, high innovation, and significant investment. A key trend is the exploration of novel targets and therapeutic modalities to address unmet needs in solid tumors and other challenging cancers.
Positioning
TScan Therapeutics is positioned as a company specializing in TCR-T cell therapy, focusing on identifying and targeting specific cancer antigens using its proprietary platforms. Its competitive advantage lies in its TargetScan and T-Scan platforms, which enable the identification of novel targets and the development of highly specific TCR-T cell therapies.
Total Addressable Market (TAM)
The global cell therapy market is estimated to reach hundreds of billions of dollars in the coming years. TScan Therapeutics is positioned to capture a portion of this TAM by developing TCR-T cell therapies for specific cancer indications where there are significant unmet needs and limited treatment options.
Upturn SWOT Analysis
Strengths
- Proprietary TargetScan and T-Scan platforms for target identification.
- Focus on TCR-T cell therapy, which offers potential advantages over CAR-T.
- Pipeline of TCR-T cell therapies targeting hematologic malignancies and solid tumors.
- Experienced management team.
Weaknesses
- Clinical stage company with no approved products.
- High cash burn rate due to ongoing clinical trials.
- Reliance on successful clinical trial outcomes.
- Risk associated with manufacturing and scaling up cell therapies.
Opportunities
- Potential to develop first-in-class TCR-T cell therapies for specific cancer indications.
- Partnerships with larger pharmaceutical companies.
- Expansion of pipeline to include additional cancer targets and therapeutic modalities.
- Application of TargetScan and T-Scan platforms to other diseases.
Threats
- Competition from other biotechnology and pharmaceutical companies developing cell therapies.
- Regulatory hurdles and potential delays in clinical trials.
- Unfavorable clinical trial results.
- Challenges in manufacturing and scaling up cell therapies.
- Economic downturn affecting biotechnology funding and stock performance.
Competitors and Market Share
Key Competitors
- ATRA
- GMDA
- IOVA
- ADAP
Competitive Landscape
TScan Therapeutics competes with other cell therapy companies in the oncology space. Its advantage lies in its TargetScan and T-Scan platforms, which enable the identification of novel targets. However, it faces competition from larger companies with more established products and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its pipeline and expansion of its technology platform. Requires details from the company reports.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its TCR-T cell therapies. Analyst estimates vary depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include progressing clinical trials for TSC-100 and TSC-101, expanding its manufacturing capabilities, and forging partnerships with other organizations.
Summary
TScan Therapeutics is a promising biopharmaceutical company focused on TCR-T cell therapies. Its strengths lie in its technology platform and pipeline, but it faces challenges related to clinical development, competition, and financial resources. Successful clinical trial outcomes are crucial for the company's future growth. Investors should monitor the progress of its clinical programs and assess the competitive landscape to evaluate the company's long-term potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct their own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tscan Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-07-16 | CEO & Director Dr. Gavin MacBeath Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 200 | Website https://www.tscan.com |
Full time employees 200 | Website https://www.tscan.com | ||
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.